Update : Since writing this post, we've encountered 2 8 15 more cases of NGLY1 deficiency worldwide, all confirmed by exome or genome sequencing. If you're a parent, physician or researcher that's found a patient with a possible NGLY1 deficiency, please be aware that the phenotype for NGLY1 deficiency varies, and there can be markedly different presentation between genders. Your patient may not fit the description in this post. Please contact me immediately if you find an NGLY1 deficient patient or suspect that you have found one. We keep all patient details confidential.
The use of rDNA allows scientists to produce many products that were previously available only in limited quantities: for example, insulin, which we referred to earlier. Until the 1980s the only source of insulin for people with diabetes came from animals slaughtered for meat and other purposes. The supply was never high enough to meet demand, and this drove up prices. Then, in 1982, the . Food and Drug Administration ( FDA ) approved the sale of insulin produced by genetically altered organisms — the first such product to become available. Since 1982 several additional products, such as human growth hormone, have been made with rDNA techniques.